Liminatus Pharma (NASDAQ:LIMN – Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.03) EPS for the quarter, FiscalAI reports.
Liminatus Pharma Price Performance
Liminatus Pharma stock traded down $0.01 during trading hours on Friday, hitting $0.14. 13,204,123 shares of the stock traded hands, compared to its average volume of 21,082,184. The firm’s 50 day moving average price is $0.12 and its 200-day moving average price is $0.25. The stock has a market capitalization of $7.09 million, a price-to-earnings ratio of -0.32 and a beta of 5.35. Liminatus Pharma has a 1 year low of $0.10 and a 1 year high of $4.33.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Liminatus Pharma in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.
About Liminatus Pharma
Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.
Featured Stories
- Five stocks we like better than Liminatus Pharma
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Liminatus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liminatus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
